elvitegravir

Elvitegravir is an experimental(Of a drug) Not licensed for use in humans, or as a treatment for a particular condition. Experimental drugs are studied in clinical trials to determine their safety and efficacy, and are sometimes made available via Special Access Schemes prior to their approval. integrase inhibitor currently in phase IIIA large clinical trial designed to establish whether a drug is effective and safe enough for widespread use. Phase III studies include expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. clinical trials.

Like raltegravir (the only drug in this class approved for use in Australia) elvitegravir will be of most use to people with multiple drug reisistance.

Integrase inhibitors target an enzyme called integrase which HIV uses to integrate its genetic code into human cells. Because this is a different point of action to that targeted by other drug classes, there is a good chance that people who have failed several prior treatment regimens will benefit from this drug, especially if it is combined with an optimised background regimen.

According to the results of phase IIA smaller clinical trial designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase III study is undertaken, with a larger number of participaants, to confirm this. clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. trials, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral loadA measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma. after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate..

UPDATE March 2011

Elvitegravir appears to be working well in a Phase III clinical trial involving treatment-experienced patients, according to a March 23 press release by Gilead, the company who manufactures the drug. Though the study will last about two years (96 weeks), Gilead says the study’s primary goal has been met: comparable results between patients receiving either elvitegravir or Merck’s approved integrase inhibitor Isentress (raltegravir) for 48 weeks